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Erythropoietin protects from reperfusion-induced myocardial
injury by enhancing coronary endothelial nitric oxide production
Abstract
OBJECTIVE: Cardioprotective properties of recombinant human Erythropoietin (rhEpo) have been
shown in in vivo regional or ex vivo global models of ischemia-reperfusion (I/R) injury. The aim of this
study was to characterize the cardioprotective potential of rhEPO in an in vivo experimental model of
global I/R approximating the clinical cardiac surgical setting and to gain insights into the myocardial
binding sites of rhEpo and the mechanism involved in its cardioprotective effect. METHODS: Hearts of
donor Lewis rats were arrested with cold crystalloid cardioplegia and after 45 min of cold global
ischemia grafted heterotopically into the abdomen of recipient Lewis rats. Recipients were randomly
assigned to control non-treated or Epo-treated group receiving 5000 U/kg of rhEpo intravenously 20 min
prior to reperfusion. At 5 time points 5-1440 min after reperfusion, the recipients (n=6-8 at each point)
were sacrificed, blood and native and grafted hearts harvested for subsequent analysis. RESULTS:
Treatment with rhEpo resulted in a significant reduction in myocardial I/R injury (plasma troponin T) in
correlation with preservation of the myocardial redox state (reduced glutathione). The extent of
apoptosis (activity of caspase 3 and caspase 9, TUNEL test) in our model was very modest and not
significantly affected by rhEpo. Immunostaining of the heart tissue with anti-Epo antibodies showed an
exclusive binding of rhEpo to the coronary endothelium with no binding of rhEpo to cardiomyocytes.
Administration of rhEpo resulted in a significant increase in nitric oxide (NO) production assessed by
plasma nitrite levels. Immunostaining of heart tissue with anti-phospho-eNOS antibodies showed that
after binding to the coronary endothelium, rhEpo increased the phosphorylation and thus activation of
endothelial nitric oxide synthase (eNOS) in coronary vessels. There was no activation of eNOS in
cardiomyocytes. CONCLUSIONS: Intravenous administration of rhEpo protects the heart against cold
global I/R. Apoptosis does not seem to play a major role in the process of tissue injury in this model.
After binding to the coronary endothelium, rhEpo enhances NO production by phosphorylation and thus
activation of eNOS in coronary vessels. Our results suggest that cardioprotective properties of rhEpo are
at least partially mediated by NO released by the coronary endothelium.
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Abstract 
 
Objective: Cardioprotective properties of recombinant human Erythropoietin (rhEpo) 
have been shown in in vivo regional or ex vivo global models of ischemia-reperfusion 
(I/R) injury. The aim of this study was to characterize the cardioprotective potential of 
rhEPO in an in vivo experimental model of global I/R approximating the clinical cardiac 
surgical setting and to gain insights into the myocardial binding sites of rhEpo and the 
mechanism involved in its cardioprotective effect. 
 
Methods: Hearts of donor Lewis rats were arrested with cold crystalloid cardioplegia and 
after 45 min of cold global ischemia grafted heterotopically into the abdomen of recipient 
Lewis rats. Recipients were randomly assigned to control non-treated or Epo-treated 
group receiving 5000 U/kg of rhEpo intravenously 20 min prior to reperfusion. At 5 time 
points 5-1440 min. after reperfusion, the recipients (n=6-8 at each point) were sacrificed, 
blood and native and grafted hearts harvested for subsequent analysis.  
 
Results: Treatment with rhEpo resulted in a significant reduction in myocardial I/R 
injury (plasma Troponin T) in correlation with preservation of the myocardial redox state 
(reduced glutathione). The extent of apoptosis (activity of caspases 3 and 9, Tunel test) in 
our model was very modest and not significantly affected by rhEpo. Immuno-staining of 
the heart tissue with anti-Epo antibodies showed an exclusive binding of rhEpo to the 
coronary endothelium with no binding of rhEpo to cardiomyocytes. Administration of 
rhEpo resulted in a significant increase in nitric oxide (NO) production assessed by 
plasma nitrite levels. Immuno-staining of heart tissue with anti-phospho-eNOS antibodies 
showed that after binding to the coronary endothelium, rhEpo increased the 
phosphorylation and thus activation of endothelial nitric oxide synthase (eNOS) in 
coronary vessels. There was no activation of eNOS in cardiomyocytes. 
 
Conclusions: Intravenous administration of rhEpo protects the heart against cold global 
I/R. Apoptosis does not seem to play a major role in the process of tissue injury in this 
model. After binding to the coronary endothelium, rhEpo enhances NO production by 
phosphorylation and thus activation of eNOS in coronary vessels. Our results suggest that 
cardioprotective properties of rhEpo are at least partially mediated by NO released by the 
coronary endothelium. 
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Introduction 
 
Myocardial protection from ischemia and reperfusion (I/R) injury remains of paramount 
importance in the setting of global myocardial ischemia associated with open-heart 
surgical procedures. There has been considerable progress made to date in myocardial 
protection strategies including the use of blood cardioplegia [1]. Nevertheless, high risk 
subset of patients continue to suffer perioperatively from myocardial I/R injury as 
exhibited by prolonged contractile dysfunction, low-output syndrome, arrhythmias, 
perioperative myocardial infarction and cardiac failure leading to prolonged intensive 
care [2]. Thus, there is a compelling necessity to improve myocardial protection from I/R 
injury during open-heart surgical procedures. 
There is a large body of experimental work showing the non-haematopoietic 
cytoprotective properties of recombinant human Erythropoietin (rhEPO) in a variety of 
tissues subjected to I/R [3], including the retina [4], brain [5] and cardiovascular system 
[6]. However, primary targets and down stream mechanisms of the cardioprotective 
effect of rhEpo remain controversial. The aim of this study was to characterize the 
cardioprotective effect of rhEPO in an in vivo model of cold global I/R injury and to gain 
insights into the primary targets and down stream mechanisms involved in its 
cardioprotective effect. 
 
Materials and methods 
 
Animals 
 
Male Lewis rats (Harlan, Holland) weighing 250-300g were used as donors and 
recipients. All animals received humane care in compliance with the European 
Convention on Animal Care. This study was approved by the local institutional ethics 
committee. The animals were maintained in standard housing conditions with dry diet 
and water available ad libitum. 
 
Heterotopic heart transplantation 
 
Donor rats were anesthetized with an i.p. injection of pentobarbital (50mg/kg of body 
weight) followed by administration of 500 units of i.v. heparin. The heart was arrested 
with 10ml/kg of body weight of cold (4°C) crystalloid cardioplegic solution and stored in 
the same cardioplegic solution at 4°C until  implantation. 
Recipient rats were anesthetized with an i.p. of pentobarbital and the donor heart was 
transplanted heterotopically according to the technique of Ono and Lindsey [7]. The total 
duration of global ischemia was 45 min of which the last 15 min were needed for 
anastomoses. 
 
Experimental design 
 
Recipient rats were randomized to control non-treated or Epo-treated group receiving 
5000 U/kg of rhEpo intravenously 20 min prior to reperfusion. At 5 time points (5, 30, 
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60, 360 and 1440 min) after reperfusion the recipients (n=6-8 at each point) were 
sacrificed. Blood, native and grafted hearts were harvested for subsequent analyses.  
 
Myocardial injury and tissue stress markers 
 
Myocardial injury was assayed by monitoring of the plasma levels of cardiac troponin T 
isoform (cTnT) using electrochemiluminescent immunoassay (Roche Diagnostics, 
Switzerland). Plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP) were determined by enzymatic immunoassay (Peninsula Laboratories, 
USA).  
 
Systemic inflammatory response 
 
Interleukin-6 (IL-6) in blood plasma was assessed using Rat IL-6 Quantikine ELISA Kit 
(R&D Systems, Minneapolis, MN).  
 
Measurement of tissue ion and water content 
 
Tissue Na+ and water content were assessed after drying and burning the tissue sampled 
in metal-free concentrated HNO3 using flame photometry and gravimetry respectively. 
 
Apoptosis markers and signaling 
 
Caspase 3 and caspase 9 activities were determined in tissue homogenate using 
colorimetric peptide-based assay kits (R&D Systems). Lysates of rat endothelial cell line 
(RBE4) treated overnight with 0.5 μM staurosporine (Sigma Aldrich, St. Louis, MO) 
were used as a positive control of apoptosis [8]. The downstream product of active 
caspase 3, cleaved Poly (ADP-ribose) Polymerase (PARP) was detected using immuno-
blotting with the rat-specific (Asp214) rabbit polyclonal antibody diluted 1:1000 (Cell 
Signaling). The CardioTACS in situ apoptosis detection kit (R&D Systems) was used to 
estimate the number of TUNEL-based apoptosis-positive nuclei.  
 
Red cell, plasma and tissue reduced (GSH)/oxidized Glutathione (GSSG) measurement  
 
Blood and plasma samples were deproteinized and GSH and GSSG were detected using 
Ellmann’s reagent as described elsewhere [9]. Tissue samples used for determination of 
the GSH/GSSH levels were homogenized in equal volumes of solutions containing either 
100 mM KCl and 10 mM MOPS-KOH or 5% trichloroacetic acid (TCA) in distilled 
water. After centrifugation supernatant was used for the GSH/GSSG detection using the 
same protocol as for the blood/plasma samples (see above). 
 
Product of nitric oxide (NO) metabolism in plasma  
 
Stable product of NO oxidation, i.e. plasma nitrite level, was detected using 
chemiluminescence assay by means of CLD-88 (EcoMedica, Switzerland). Plasma 
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samples were collected immediately after blood harvest and concomitant centrifugation 
(4 min 8000 g). 
 
Epo-induced signaling 
 
Binding of rhEpo was assessed in acetone-fixed cryosections of transplanted and native 
ventricular tissue using antibodies against Epo (R&D Systems).  
Rabbit polyclonal antibodies against phosphorylated (Ser 1177) eNOS (Cell Signaling, 
1:100) were used for immunohistochemical determination of eNOS phosphorylated 
eNOS in acetone-fixed frozen sections. Secondary FITC-conjugated antibodies were 
applied and localization of the specific staining determined using fluorescent microscopy 
(Zeiss AxioScope 2500). 
 
K+ influx measurements in neonatal rat cardiomyocytes  
 
The procedure of cell isolation is described in details elsewhere [10]. Unidirectional K+ 
influx was measured using radioactive tracer technique. The cells (≈400’000 cells per 
Petri dish, 3 cm ∅) were pre-treated with 1 mM ouabain and/or rhEpo (final activity 10 
U/ml) in the presence or absence of 100 μM L-arginine for 30 minutes. Thereafter flux 
detection was initiated by adding 86Rb as a tracer for K+ (final activity 0.5 μCi/ml). 
Fluxes were assessed over half an hour with tracer accumulation detected 5, 10, 20 and 
30 min after the tracer application. Over this time period the accumulation of tracer was a 
liner function of the incubation time. Samples (10μl)  of the incubation media were 
collected and the cells were washed free from extracellular 86Rb with ice-cold incubation 
medium and finally lysed in 0.1 M NaOH. Cell lysate was then used for detection of the 
intracellular 86Rb and protein assessment (Bio-Rad protein assay). Unidirectional 
potassium influx was then calculated from the slope of the 86Rb uptake curve over time 
and normalized per amount of the 86Rb in the incubation medium and per protein. Active 
K+ transport mediated by the Na/K ATPase was calculated as a difference between K+ 
fluxes in the presence and in the absence of ouabain. Ouabain-resistant flux component 
was addressed to as passive K+ influx. 
 
Statistical Analysis 
 
All data are based on at least 6 replicates for in vivo experiments and at least 5 
independent experiments when using cultured cardiomyocytes. They are presented as 
mean ± SEM. The comparison between the experimental groups was performed using 
ANOVA and two-tailed Student's t-test for unpaired samples with normality test and 
Bonferroni-correction when analyzing simple time points (GraphPad Instat.V3.05). The 
optimal number of experiments per time point and group was chosen in accordance with 
our previous experience [11]. The level of statistical significance was set at p < 0.05. 
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Results 
 
rhEpo and I/R myocardial damage   
 
Significant reduction of the cardiac TnT plasma levels in the rhEpo-treated group 
indicated that intravenous application of the rhEpo could efficiently reduce both early and 
late reperfusion-induced myocardial injury (Fig 1). In particular, hrEpo abolished acute 
release of the atrial and brain natriuretic factors into the circulation upon restoration of 
blood perfusion of the graft (Fig 2). Systemic inflammatory response assessed as an 
increase in plasma IL 6 level 6 hours after the onset of perfusion was not affected by 
hrEpo treatment (235±72 vs. 291±67 pg/ml in control and hrEpo-treated recipients, 
p>0.05). Thus cardioprotective effect of Epo was not due to the suppression of the 
secondary inflammatory response.  
The time from the onset of reperfusion to the defibrillation of the grafted heart was 
shorter in rhEpo-treated than non-treated group (47±2 vs. 66±4 sec, respectively, n=40, 
p=00012).  
 
Mechanisms of I/R injury 
Interaction of hrEpo with its receptor was shown to reduce apoptosis in isolated 
cardiomyocytes [3]. We have evaluated the degree of apoptosis in transplanted hearts of 
control and hrEpo-treated animals as well as between the transplanted and native hearts.   
To do so we have assessed caspase 9 and caspase 3 activity in ventricular tissue 
homogenate. The resulting activity was compared between native and transplanted hearts 
in both control and Epo-treated animal groups and related to the activity of caspases in 
cell culture where apoptosis was triggered by staurosporine treatment. The basal activity 
of caspase 3 and 9 in the native heart tissue was very low (0.28% of the positive 
control,staurosporine-treated vascular endothelial cells) for caspase 3 and 0.20 % of the 
positive control for caspase 9). Ischemia-reperfusion resulted in a very modest increase of 
the activity of both caspases which was only statistically significant between the native 
and the transplanted hearts 30 min after the onset of perfusion (data not shown). This 
difference was insignificant when caspases’ activity in transplanted hearts of Epo-treated 
group were compared to the native heart levels. Activation of caspase 3 did not cause 
detectible PARP cleavage in transplanted hearts at any reperfusion time point. In 
addition, the number of TUNEL-positive cells ranged between 0 and 4 cells/x20 field and 
did not differ statistically between non treated and rhEpo treated ischemic hearts. Taken 
together with the data on cardiac TnT release into the circulation these data suggest that 
most of the ischemia-reperfusion damage represents oncosis rather than apoptosis.  
 
Cellular ion and water content 
Data on tissue water and sodium content shown in Fig 3A and B provide further 
confirmation for the preferential oncotic acute reperfusion damage. Reperfusion is 
followed by a transient increase in tissue sodium and water levels in transplanted hearts 
of control but not in rhEpo-treated animals. Recovery of the tissue ion/water balance 
occurred within 30 min of reperfusion in both control grafts and rhEpo-treated grafts. 
  
Reperfusion and oxidative stress 
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Oxidation is one of the recognized causes of the myocardial damage at reperfusion. 
Indeed, reperfusion resulted in acute depletion of the GSH pool in ventricular tissue that 
became even more pronounced with time (Fig 4A). Administration of rhEpo resulted in 
an increase in the GSH content in native myocardium (p<0.05). Transplanted hearts of 
the hrEpo-treated group did not show GSH depletion at any reperfusion time point (Fig 
4A). Intravenous administration of hrEpo also abolished reduction of the GSH levels in 
erythrocytes and plasma of the recipient animals thus providing systemic defense from 
the reperfusion-induced oxidative stress (Fig 4B and C). 
 
Mechanisms of the cardioprotective action of hrEpo 
As shown in Figs 4 and 3, hrEpo protects transplanted myocardium from reperfusion-
induced oxidative stress, edema and Na+ accumulation. Plasma nitrite levels in recipient 
animals were significantly up-regulated following hrEpo administration indicating an 
increase in nitric oxide production (Fig 5). The source of NO production was 
characterized by using antibodies against phosphorylated (active) form of endothelial 
nitric oxide synthase (eNOS). Interestingly, hrEpo treatment resulted in activation of 
eNOS selectively in vascular endothelium of coronary vessels but not in the myocardial 
tissue itself (Fig 6C,D). Cardiac myocytes are known to express eNOS along with 
vascular endothelial cells. We therefore investigated localization of hrEpo in both native 
and transplanted heart tissue. The data presented in Fig 6A and B indicate that hrEpo 
does not diffuse from the lumen of the coronary vessels into the myocardium at least for 
the first 30 min of reperfusion. Both the hrEpo binding and activation of the eNOS are 
restricted to the endothelial compartment.  
In order to address the possible effect of hrEpo on ion and water equilibrium in more 
details we have monitored the active and passive K+ transport across the sarcolemmal 
membrane of primary cultures of cardiac myocytes in the presence and in the absence of 
hrEpo. Administration of hrEpo resulted in stimulation of the active influx of K+ 
mediated by the Na/K ATPase along with suppression of passive K+ movement across 
the sarcolemma (Fig 7A). This does not occur when the cell incubation medium is 
deprived of  L-arginine, a substrate of eNOS (Fig 7B) suggesting the observed effects of 
hrEpo on both the Na/K ATPase and the passive K+ flux are not direct but secondary to 
the Epo-induced stimulation of NO production.  
 
 
Discussion 
 
Choosing an in vivo model of cold global ischemia and warm reperfusion we intended to 
mimic as closely as possible the clinical setting during open-heart surgical procedures. 
The narrow time window of cardioprotection for rhEpo makes it almost useless when 
treating myocardial infarction (first hours after the injury) [3,12]. The pre-operative 
period on the contrary allows precisely timed administration of the drug assuring 
maximal cardioprotective effect of rhEpo. To our knowledge, the present study is the first 
one investigating the myocardial action of rhEpo during cold global I/R injury in vivo. 
Our data indicate that in i.v. administration of rhEpo after the onset of cold global 
ischemia but prior to warm reperfusion confers an acute cardioprotective effect in rats. 
This cardioprotection offered by rhEpo was not linked to the suppression of apoptosis but 
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to the reduction of oxidative stress and edema, which was at least partially mediated by 
the rhEpo-induced stimulation of NO production.  
 
This observation is in line with numerous reports of cardioprotective efficiency of rhEpo 
obtained using different models and experimental setting including isolated rat 
cardiomyocytes [6, 13-15], in vitro Langendorff model [6,13, 16-18] and in vivo 
coronary artery ligation model [12, 14, 15, 19]. Despite extensive investigations the 
mechanisms of rhEpo-induced cardioprotection remain a matter of debate. Data 
generated using primarily isolated cardiomyocytes, but also in some in vivo models 
suggest that rhEpo protects myocardium from apoptosis [12, 15]. However, the role of 
apoptosis of cardiomyocytes in I/R injury is questionable [1, 20]. Our data reveal that, 
although occurring, apoptosis does not contribute significantly to the cold global I/R 
injury in our experimental model. Reperfusion induced only marginal activation of 
caspases 9 and 3 at only one time point (30 min of reperfusion).  However, at 30 min of 
reperfusion rhEpo administration significantly reduced myocardial cell injury reflected 
by plasma troponin (Fig.1). Of note, reduction in mechanical overload evidenced by ANP 
and BNP release into the plasma was detectible even earlier, already 5 min after the onset 
of blood flow (Fig 2). We were unable to monitor the changes in downstream targets of 
caspase activation such as PARP cleavage or DNA fragmentation suggesting that when 
occurring, apoptotic response was incomplete. Very close to our results, van der Meer 
and co-workers found only a modest proportion of apoptotic cells positive for active 
caspase 3 in rat hearts subjected to ischemia-reperfusion with (1.8 ±0.09%) or without 
(2.1 ±0.12%) rhEpo treatment [18]. Interestingly, activation of the caspase 3 in their 
study was mainly restricted to the endothelial cells and fibroblasts. This finding is further 
supported by Scarabelli and co-workers reporting that apoptosis of endothelial cells 
precedes cardiomyocyte cell apoptosis in ischemia/reperfusion injury [20]. Parsa and co-
workers suggested a potential role of cardiac fibroblasts in modulating cardioprotective 
effects of Epo in hearts subjected to ischemia-reperfusion [14].  
 
Edema and Na+ accumulation in the myocardial tissue we have observed (Fig 3) as well 
as delayed inflammatory response are also not consistent with the concept of apoptosis as 
a dominating course of I/R injury. Histological examination revealed extensive 
myocardial lesions where cell membranes lacked integrity that became detectible already 
30 min after the onset of perfusion when cardiac TnT was detected in plasma of recipient 
animals (Fig 1). Taken together these findings suggest that most of the myocardial 
damage represented oncotic necrosis.  
 
Our data furthermore indicate that intravenous rhEpo administration would fail to 
suppress apoptosis in the myocardium even if the later were occurring for one single 
reason: rhEpo does not cross the endothelial barrier and hence does not reach the 
myocardium at least during the first hours of reperfusion (Fig 6). Thus, data obtained for 
interaction of the cytokine with isolated cardiomyocytes [15] cannot be compared with 
those obtained using ex vivo or in vivo models. The target for rhEpo applied 
intravenously is primarily the endothelium of coronary vessels. Upon binding to the 
endothelial cells occurring instantaneously (Fig 6) rhEpo causes activation of the NO 
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production (Fig 5)  and most likely other factors such as endothelin 1 [17] that are 
mediating cardioprotective effects observed by us and others.           
 
Among the final targets of the rhEpo are reduction of mechanical overload monitored as 
release of the stress factors ANP and BNP, abrogation of the reperfusion-induced 
oxidative stress (Fig 4) and accelerated recovery of the ion and water balance in the 
myocardial tissue (Fig 3). It is unlikely that the observed multiple effects are caused by 
activation of a single signaling pathway. Detailed investigation of involved molecular 
events in potential signaling pathways is by far beyond the scope of this study. Similar 
suppression of the ANP and BNP release upon reperfusion following ischemia in rhEpo-
treated animal models was reported by others [17, 19]. Antioxidative effect of rhEpo was 
also shown in different tissues and experimental settings [3].  
We suggest that activation of the NO production in the endothelial cells is at least in part 
responsible for the lack of GSH depletion in myocardial tissue during reperfusion. There 
is long-standing debate as to whether NO play a beneficial or detrimental role in 
ischemia-reperfusion injury. It seems tempting to extrapolate the results of in vitro 
experiments using cell cultures to the in vivo pathogenic conditions [21]. Redox 
environment is the factor decisive for both NO bioavailability and the end products 
formed which may include both nitrite, nitrate, S- and N-nitrosylation adducts and nitro-
tyrosine. It has been shown that lower levels of NO production and diffusion into the 
tissue are associated with its anti-oxidative properties [22].  The redox environment can 
in turn modulate the NO function and potentiate its cardioprotective action. This 
multifaceted action of NO defines its narrow therapeutic safety window for NO in 
ischemia-reperfusion pathophysiology [22]. In the present study, administration of rhEpo 
was followed by increased phosphorylation and activation of eNOS with subsequent 
enhanced production of NO during the early phase of reperfusion. Up-regulation of NO 
production was associated with reduction of oxidative stress and consequently of 
myocardial injury. This is in accordance with previous report of Bullard and co-workers 
who showed that the cardioprotective effect of Epo was associated with a 2-fold increase 
in phosphorylated eNOS [13].       
 
Along with its role as a scavenger of superoxide anions NO has been shown to modulate 
numerous processes including ion transport [23]. In our study, reduction in myocardial 
injury was also accompanied by a decrease in tissue edema and Na+ accumulation. We 
demonstrated that activation of the NO production triggered by rhEpo treatment of 
neonatal rat cardiomyocytes (our observations as well as [13, 17, 21]) modulated Na/K 
ATPase activity. This is the first report on the role of NOS in regulation of the active K+ 
transport in cardiomyocytes. However, our recent study revealed similar coupling 
between NOS-mediated NO production and activity of the Na/K ATPase in cerebellar 
granule cells [23]. Along with activation of the Na/K ATPase reduction of the passive K+ 
fluxes is observed in the cardiomyocytes where NO generation is induced by rhEpo 
furthermore facilitating restoration of the transmembrane ion gradients (Fig 7).  
 
 
There are limitations in the present study related to its design. Focusing mainly on 
investigating the mechanisms of Epo-induced cardioprotection, we chose a fixed dose at 
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a fixed time of administration of rhEpo. However, the dose of 5’000 U/kg rhEpo used in 
our study has been shown to confer significant cardioprotection against ischemia-
reperfusion [12]. After demonstrating the cardioprotection conferred by rhEpo, we 
limited our study to the potential  role of NO alone. We cannot exclude that other local or 
systemic factors modulated by rhEpo such as endothelin 1, vascular endothelial growth 
factor and transforming growth factor may play a significant role in the acute and late 
cardioprotection induced by rhEpo [3, 17]. The involvement of other secondary effectors 
in the cardioprotection offered by rhEpo warrants further investigations. Moreover, our 
rodent model does not allow to assess clinical relevance of the obtained results but gives 
insight for further characterization of mechanisms of potential cardioprotection offered 
by Epo in human settings. 
 
In summary, intravenous administration of rhEpo after the onset of ischemia but prior to 
reperfusion protects the heart against cold global I/R. Apoptosis does not seem to play a 
major role in the process of tissue injury in this model. After binding to the coronary 
endothelium, rhEpo enhances NO production by phosphorylation and thus activation of 
endothelial nitric oxide synthase in coronary vessels. Our data suggest that 
cardioprotective properties of rhEpo are at least partially mediated by nitric oxide 
released by the coronary endothelium. 
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Figure legends 
 
Fig 1  
Plasma Troponin T levels. Data are means of 6-8 independent experiments ± SEM (n=6-
8). * indicates p<0.05 compared to the corresponding time point in non-treated control 
group.  
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Fig 2 
A- Plasma levels of atrial natriuretic peptide ANP in non-treated control animals (Basal) 
and 5min after the onset of reperfusion in non-treated control animals (Control) and 
rhEpo-treated animals (Epo). Data are means of 6-8 independent experiments ± SEM. * 
indicates p<0.05 compared to the corresponding time point in non-treated control group. 
B- Plasma levels of brain natriuretic peptide BNP in non-treated control animals (Basal) 
and 5 min after the onset of reperfusion in non-treated control animals (Control) and 
rhEpo-treated animals (Epo). Data are means of 6-8 independent experiments ± SEM. * 
indicates p<0.05 compared to the corresponding time point in non-treated control group. 
 
 
Fig 3 
Effect of I/R and hrEpo on the tissue water and Na+ content. A. Water content in 
ventricular tissue of native non-ischemic hearts of the non-treated control group (Native) 
and in ischemic reperfused hearts of non-treated control group (Control) and rhEpo-
treated group (Epo) 5 minutes after the onset of perfusion. B. Tissue Na+ content in the 
same set of samples. Data are means of 6-8 hearts ± SEM. * indicates p<0.05 compared 
to the value in native hearts.  
  
Fig 4   
Reduced glutathione levels in ventricular tissue homogenates of native non-treated 
(n.control) and native rhEpo-treated (n.Epo) hearts, erythrocytes and plasma. 
A: GSH pool of ventricular tissue. Values are means of 6-8 independent heart samples 
±SEM. Note that the values for native hearts differ between the control and rhEpo-treated 
animals (denoted with #, p<0.05). * indicates p<0.05 compared to the native control 
value. B and C: GSH levels in erythrocytes and plasma. Data are means of 6-8 
experiments ± SEM. # indicates p<0.05 compared to the levels in non-treated control 
animals of the corresponding time point. * denotes p<0.05 compared to the basal level in 
non-treated animals.  
 
Fig 5 
Nitrite levels in plasma of rhEpo-treated animals (rhEpo) and non-treated control animals 
(Control). Data are means of 6-8 animals ± SEM.  * denotes p<0.05 compared to the 
corresponding time point in non-treated control animals. 
 
Fig 6 
Localization of the rhEpo binding (stained in red) and eNOS activation (phosphorylated 
active form stained in green) in the grafts.  
rhEpo localization in the ventricular tissue of the grafts 5 min after the onset of 
reperfusion (A) and 30 min after the onset of perfusion (B). Localization of the phospho-
eNOS (antibodies against phosphor-Ser1177) in the transplanted hearts 5 min (C) and 30 
min (D) after the onset of perfusion.      
 
Fig 7 
Total, passive and active K+ influx components into neonatal rat cardiomyocytes in the 
presence or in the absence of 10 U/ml rhEpo in the medium containing 100 μM L-
 14
arginine (A) or in arginine-free medium (B). Data are means of 5 independent 
experiments ±SEM. *** and * indicates p<0.001 and p<0.05 correspondingly when 
compared to the Epo-free conditions. 
 
 







